Moderna raises 2021 sales forecast for COVID-19 vaccine to $19.2 billion
Moderna Inc raised its 2021 sales forecast for its COVID-19 vaccine by 4.3% to $19.2 billion on Thursday, reflecting demand from countries looking to return to normalcy through rapid inoculation, Trend reports with reference to Reuters.
Earlier this week, Larger rival Pfizer Inc said it expects $26 billion in sales of its COVID-19 vaccine this year. read more
Moderna had in February forecast vaccine sales of $18.4 billion.
Since then, wealthy nations have been stocking up shots from Moderna and Pfizer Inc /BioNTech SE after safety concerns and production problems temporarily sidelined AstraZeneca Plc and Johnson & Johnson vaccines.
In the first quarter ended March 31, Moderna's vaccine brought in sales of $1.7 billion.
The company said it plans to file for full approval of the vaccine in the United States this month.